CCS
SGNT

Crosspoint Capital Strategies’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Crosspoint Capital Strategies’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-63
Closed -$1K – 1320
2015
Q3 		$1K Buy
+63
New +$1.36K ﹤0.01% 723

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Crosspoint Capital Strategies's SGNT Position: Q4 2015 in Review

Crosspoint Capital Strategies sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q4 2015, closing a stake of 63 shares — an estimated $1K sold.

Crosspoint Capital Strategies first reported a position in SGNT in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 134 funds tracked by Wall St. Rank hold SGNT as of Q4 2015.

  • Crosspoint Capital Strategies reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q4 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 63 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q4 2015, an estimated $1K.
  • Crosspoint Capital Strategies first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $1K in Q3 2015.
  • 134 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q4 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2015, filed 16 Feb 2016.